Search clinical trials for: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

Total 11 results

Peking University People's Hospital
Ministry of Science and Technology of the People´s Republic of China

Not yet recruiting

Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL (RIF)

Acute Promyelocytic Leukaemia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaborators

Recruiting

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol (SCCCG-R-ALL)

Childhood ALL | Arsenic Trioxide

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Acute Myeloid Leukemia

China
Junmin Li

Suspended

Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

Chronic Myelogenous Leukemia

China
Peking University People's Hospital

Recruiting

Optimum Induction Therapy of Low-risk APL

Acute Promyelocytic Leukemia | Oral | Induction Therapy

China
First Affiliated Hospital Xi'an Jiaotong University
Tang-Du Hospital

Recruiting

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) (APL16)

Acute Promyelocytic Leukemia

China
South China Children's Leukemia Group

Completed

A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia

Childhood Acute Promyelocytic Leukemia

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia
National Cancer Institute (NCI)

Not yet recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma

Search clinical trials for: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations